Table 2 Correlations between RCB-TILs and clinicopathological parameters in 61 triple-negative, 36 HER2-positive, and 80 hormone receptor-positive breast cancers
Parameters | TNBC (n = 61) | p value | HER2BC (n = 36) | p value | HRBC (n = 80) | p value | |||
|---|---|---|---|---|---|---|---|---|---|
Positive (n = 49) | Negative (n = 12) | Positive (n = 26) | Negative (n = 10) | Positive (n = 37) | Negative (n = 43) | ||||
Age at operation | |||||||||
≤ 56 | 23 (46.9%) | 5 (41.7%) | 12 (46.2%) | 4 (40.0%) | 17 (45.9%) | 26 (60.5%) | |||
> 56 | 26 (53.1%) | 7 (58.3%) | 0.743 | 14 (53.8%) | 6 (60.0%) | 0.519 | 20 (50.1%) | 17 (39.5%) | 0.194 |
Menopause | |||||||||
Pre-menopausal | 17 (34.7%) | 5 (41.7%) | 11 (42.3%) | 3 (30.0%) | 16 (43.2%) | 20 (46.5%) | |||
Post-menopausal | 32 (65.3%) | 7 (58.3%) | 0.652 | 15 (57.7%) | 7 (70.0%) | 0.389 | 21 (56.8%) | 23 (53.5%) | 0.770 |
Tumor size | |||||||||
≤ 2 cm | 7 (14.3%) | 0 (0.0%) | 5 (19.2%) | 1 (10.0%) | 7 (18.9%) | 4 (9.3%) | |||
> 2 cm | 42 (85.7%) | 12 (100.0%) | 0.197 | 21 (80.8%) | 9 (90.0%) | 0.456 | 30 (81.1%) | 39 (90.7%) | 0.179 |
Lymph node status | |||||||||
Negative | 9 (18.4%) | 2 (16.7%) | 8 (30.8%) | 3 (30.0%) | 10 (27.0%) | 9 (20.9%) | |||
Positive | 40 (81.6%) | 10 (83.3%) | 0.630 | 18 (69.2%) | 7 (70.0%) | 0.647 | 27 (73.0%) | 34 (79.1%) | 0.353 |
Nuclear grade | |||||||||
1, 2 | 37 (75.5%) | 7 (58.3%) | 19 (73.1%) | 9 (90.0%) | 25 (67.6%) | 40 (93.0%) | |||
3 | 12 (24.5%) | 5 (41.7%) | 0.234 | 7 (26.9%) | 1 (10.0%) | 0.269 | 12 (32.4%) | 3 (7.0%) | 0.004 |
Ki67 | |||||||||
≤ 14% | 13 (26.5%) | 5 (41.7%) | 10 (38.5%) | 7 (70.0%) | 13 (35.1%) | 26 (60.5%) | |||
> 14% | 36 (73.5%) | 7 (58.3%) | 0.303 | 16 (61.5%) | 3 (30.0%) | 0.090 | 24 (64.9%) | 17 (39.5%) | 0.024 |
Pathological response | |||||||||
pCR | 26 (53.1%) | 2 (16.7%) | 9 (34.6%) | 9 (90.0%) | 15 (40.5%) | 6 (14.0%) | 0.007 | ||
non-pCR | 23 (46.9%) | 10 (83.3%) | 0.023 | 17 (65.4%) | 1 (10.0%) | 0.004 | 22 (59.5%) | 37 (86.0%) | |